In conclusion, even though the activation and expression of PPARs in HCC development continues to be controversial, in recent years, complementary therapies have been developed that mainly involve PPARα and PPARγ-activation, sensitizing tumor cells to traditional anticancer treatments used in HCC. The gene discussed is PPARG; the disease is hepatocellular carcinoma.